CLINICAL TRIALS

WHAT IS A CLINICAL TRIAL?
A clinical trial is a type of research study that aims to explore whether a medical treatment is safe and effective for humans.

DO YOU NEED A CLINICAL TRIAL?
If you have liposarcoma progression despite the use of standard therapies and surgery, you or your doctor may want to investigate a clinical trial as an option for your treatment plan. While clinical trials are technically considered research, many liposarcoma patients have benefited from participation. Each clinical trial is designed for a specific purpose or condition.

WHAT ARE THE BENEFITS?

• The option of gaining access to new treatments after standard therapy fails.
• The opportunity to be the first to benefit from a new method under study.
• Receiving treatment at a major liposarcoma trial center.
• Close monitoring, advice, care, and support by a research team who has a better understanding of your disease or condition.
• The chance of helping future liposarcoma patients by contributing to medical research.

WHAT ARE THE RISKS?

• The new drug may not work for you.
• There may be unpleasant side effects as a response to the experimental treatment.
• Additional testing, time, and travel may be required.
• Some costs may not be covered by insurance companies.

 

CURRENT CLINICAL TRIALS:

BTX-A51 in Patients with Liposarcoma

• Locations: Brigham and Women’s Hospital, Boston, Massachusetts, 02215, United States; Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States
• Status: RECRUITING
• Conditions: Liposarcoma, Recurrent Liposarcoma, Metastatic Liposarcoma, Unresectable Liposarcoma, MDM2 Gene Amplification
• Interventions Drug: BTX-A51
• Brief Summary: This study is testing if the recommended dose of BTX-A51 is safe and tolerable in participants with liposarcoma…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06414434

 

Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone. (TRABEPIO)

• Locations: Fondazione IRCCS Istituto Nazionale Tumori, Milano, MI, 20133, Italy
• Status: RECRUITING
• Conditions: Liposarcoma, Myxoid; liposarcoma, Dedifferentiated; Liposarcoma, Round Cell
• Interventions Drug: Trabectedin; Drug: Pioglitazone Oral Product
• Brief Summary: This is a phase 2 study conducted in two sequential stages…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04794127

 

A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)

• Locations: Oslo University Hospital HF, Oslo, Norway (NOT YET RECRUITING); Sahlgrenska University Hospital, Göteborg, Sweden; Skane University Hospital, Lund, Sweden
• Status: RECRUITING
• Conditions: Dedifferentiated Liposarcoma
• Interventions Drug: Pemigatinib; Drug: Retifanlimab
• Brief Summary: Dedifferentiated liposarcomas (DDLPS) are aggressive soft tissue sarcomas…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06389799

 

International Prospective Registry on Local Treatment Approaches in MLS

• Locations: The Netherlands Cancer Institute, Amsterdam, 1066CX, Netherlands
• Status: RECRUITING
• Conditions:  Myxoid Liposarcoma
• Interventions Procedure: Surgery; Radiation: Preoperative RT 36Gy; Radiation: Preoperative RT 50Gy; Radiation: Postoperative RT 50-66Gy; Radiation: RT 36Gy
• Brief Summary: To prospectively study commonly used local treatment approaches in Myxoid Liposarcoma (MLS)…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04699292

 

Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients (TRASTS)

• Locations: Institut Bergonie, Bordeaux, 33000, France; Centre Leon Berard, Lyon, France; Istituto Clinico Humanitas, Rozzano, Milan, 20089 (NOT YET RECRUITING), Italy; Centro di Referimento Ocologico, Aviano, 33081, Italy (NOT YET RECRUITING); Istituto Ortopedico Rizzoli, Bologna, 40136, Italy (NOT YET RECRUITING); Candiolo Cancer Institute, Candiolo, 10060, Italy; Istituto Nazionale dei Tumori, Milan, 20133, Italy; Hospital Miguel Servet, Zaragoza, Aragon, 50009, Spain; Hospital Sant Pau, Barcelona, Cataluña, 08041, Spain; Hospital Son Espases, Palma de Mallorca, Mallorca, 07010, Spain; Hospital Universitario Canarias, San Cristobal de la Laguna, Tenerife, 38320, Spain; Hospital Vall d’Hebron, Barcelona, 08035, Spain; Hospital Puerta de Hierro, Madrid, 28006, Spain; Hospital Universitario Gregorio Maranon, Madrid, 28007, Spain; Hospital Uniersitario La Paz, Madrid, 28046, Spain; Jimenez Di­az Foundation University Hospital, Madrid, Spain; Hospital Virgen del Roci­o, Sevilla, 41013, Spain
• Status: RECRUITING
• Conditions: Liposarcoma, Myxoid; Sarcoma, Soft Tissue; Leiomyosarcoma; Liposarcoma; Pleomorphic Liposarcoma
• Interventions Drug: Trabectedin; Radiation: Radiotherapy
• Brief Summary: Phase I-II trial that combines trabectedin plus radiotherapy for tumor reduction response measure in four cohorts of patients…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT02275286

 

APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors

• Locations: Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China; Cancer Hospital of The University of Chinese Academy of Sciences, Hangzhou, Zhejiang, 310005, China; Shanghai East Hospital (East Hospital affiliated to Tongji University), Shanghai, China
• Status: RECRUITING
• Conditions: Liposarcoma; Advanced Solid Tumor
• Interventions Drug: APG-115; Drug: Toripalimab
• Brief Summary: Part 1 is a phase Ib standard “3 + 3” design, will be employed to determine the MTD of APG-115 by assessing the DLT of APG-115 in combination with PD-1 inhibitor(toripalimab) in advanced solid tumors. Part 2 is a Simon two-stage phase II study design. At RP2D of APG-115 in combination with toripalimab in advanced liposarcoma, approximately 34 patients will be treated with the combination until disease progression, unacceptable toxicity, or another discontinuation criterion is met…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04785196

 

Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas (ESPACE)

• Locations: Institut du Cancer de Montpellier – Val d’Aurelle, Montpellier, 34298, France
• Status: RECRUITING
• Conditions: Liposarcoma; Atypical Lipomatous Tumor
• Interventions Diagnostic Test: Blood sampling
• Brief Summary: The main objective of this project is to identify a new non-invasive biological test for the diagnosis of LPS by measuring circulating serine levels. The current gold standard is the detection of Mdm2 amplification by the FISH…
  More information and eligibility requirements can be found here: STUDY: NCT04224064

 

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma (STRASS2)

• Locations: See link below for various location options.
• Status: RECRUITING
• Conditions:  Retroperitoneal Sarcoma; Liposarcoma; Leiomyosarcoma
• Interventions Procedure: Surgery; Drug: Preoperative chemotherapy
• Brief Summary: This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival… For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04031677

 

Genomic Risk in Retroperitoneal Sarcoma

• Location: Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States
• Status: RECRUITING
• Conditions: Retroperitoneal Liposarcoma; Soft Tissue Sarcoma
• Interventions Other: Biospecimen sample collection during standard-of-care surgery
• Brief Summary: The protocol intends to explore the biology which may underlie recurrences of retroperitoneal liposarcoma. Surgery remains the only curative intent intervention for this disease…
  More information and eligibility requirements can be found here: STUDY: NCT06436846

 

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

• Locations: St. Jude Children’s Research Hospital, Memphis, Tennessee, 38105, United States
• Status: RECRUITING
• Conditions:  Non-rhabdomyosarcoma; Adipocytic Neoplasm; Liposarcoma
• Interventions Procedure: Surgical resection; Radiation: Proton beam radiation therapy; Drug: Pazopanib; Drug:Ifosfamide; Drug: Doxorubicin; Drug: Selinexor
• Brief Summary: The study participant has been diagnosed with non-rhabdomyosarcoma (NRSTS)…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06239272

 

Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1

• Locations: MD Anderson Cancer Center, Houston, Texas, 77030, United States
• Status: RECRUITING
• Conditions: Synovial Sarcoma; Myxoid/Round Cell Liposarcoma
• Interventions Drug: Fludarabine phosphate; Drug: NY-ESO-1 TCR/IL-15 NK; Drug: Cyclophosphamide
• Brief Summary: The goal of this clinical research study is to find a recommended dose of donated NK cells that can be given along with chemotherapy to patients with advanced cancers. The safety and effects of this therapy will also be studied…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06083883

 

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4i)

• Locations: See link below for various location options.
• Status: RECRUITING
• Conditions: Liposarcoma; Prostate Cancer; Breast Neoplasms; Adenocarcinoma of Lung
• Interventions Drug: PF-07220060; Combination Product: Letrozole; Combination Product: Fulvestrant; Drug:Midazolam; Combination Product: Enzalutamide
• Brief Summary: This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and then in combination with endocrine therapy…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04557449

 

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

• Locations: Texas Children’s Hospital, Houston, Texas, 77030, United States
• Status: RECRUITING
• Conditions: Liver Cancer; Rhabdomyosarcoma; Malignant Rhabdoid Tumor; Liposarcoma; Wilms Tumor; Yolk Sac Tumor
• Interventions Genetic: CARE T cells; Drug: Cytoxan; Drug: Fludara
• Brief Summary: Patients may be considered if the cancer has come back, has not gone away after standard treatment or the patient cannot receive standard treatment. This research study uses special immune system cells called CARE T cells, a new experimental treatment …
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04715191

 

Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

• Locations: Texas Children’s Hospital, Houston, Texas, 77030, United States
• Status: RECRUITING
• Conditions: Liver Cancer; Rhabdomyosarcoma; Malignant Rhabdoid Tumor; Liposarcoma; Wilms Tumor; Yolk Sac Tumor
• Interventions Genetic: AGAR T cells
• Brief Summary: Patients may be considered if the cancer has come back, has not gone away after standard treatment or the patient cannot receive standard treatment. This research study uses special immune system cells called AGAR T cells, a new experimental treatment…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04377932

 

BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors (DUET-1)

• Locations: Baylor Scott and White Research Institute, Dallas, Texas, 75246, United States; University of Texas MD Anderson Cancer Center, Houston, Texas, 77030-4008, United States; Froedtert and Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States
• Status: RECRUITING
• Conditions: Hepatocellular Carcinoma; Squamous Cell Carcinoma of the Lung; Merkel Cell Carcinoma; Myxoid/Round Cell Liposarcoma
• Interventions Biological: CAR-GPC3 T Cells
• Brief Summary: This is a first-in-human (FIH), Phase 1/2, open-label, multicenter study to assess safety and determine the recommended Phase 2 dose (RP2D) of BOXR1030 administration after lymphodepleting chemotherapy (LD chemotherapy) in subjects with glypican-3 positive (GPC3+) advanced solid tumors…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05120271

 

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

• Locations: Krankenhaus Nordwest, Frankfurt, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Universitatsklinikum Tubingen, Tubingen, Germany
• Status: RECRUITING
• Conditions: Melanoma (Skin); Triple-Negative Breast Cancer; Non-Small Cell Lung Cancer; Synovial Sarcoma; Myxoid Liposarcoma; Colorectal Cancer
• Interventions Biological: PeptiCRAd-1; Drug: Cyclophosphamide; Drug: Pembrolizumab
• Brief Summary: This study is being conducted to explore the immunological mechanism of action of Peptide-coated Conditionally Replicating Adenovirus-1 (PeptiCRAd-1) plus Checkpoint inhibitor (CPI) therapy in multiple cancer types, as well as to obtain early information on the safety of this combination therapy…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05492682

 

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

• Locations: National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, 20892, United States; Dana-Farber – Harvard Cancer Center LAO, Boston, Massachusetts, 02115, United States; Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States; University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, 48109, United States (SUSPENDED); University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, 15232, United States; M D Anderson Cancer Center, Houston, Texas, 77030, United States
• Status: RECRUITING
• Conditions: Metastatic Dedifferentiated Liposarcoma; Metastatic Leiomyosarcoma; Metastatic Myxofibrosarcoma; Metastatic Sarcoma; Metastatic Synovial Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Unresectable Dedifferentiated Liposarcoma; Unresectable Leiomyosarcoma; Unresectable Myxofibrosarcoma; Unresectable Sarcoma; Unresectable Synovial Sarcoma; Unresectable Undifferentiated Pleomorphic Sarcoma
• Interventions Procedure: Biopsy; Procedure: Biospecimen Collection Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Drug: Pegylated Liposomal Doxorubicin Hydrochloride; Drug:Peposertib
• Brief Summary: This phase I trial tests the safety, side effects, and best dose of combination therapy with liposomal doxorubicin and peposertib in treating patients with sarcoma that has spread from where it first started, to other places in the body (metastatic), or cannot be removed by surgery (unresectable) and for which no known cure is available (advanced)…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05711615

 

A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.

• Locations: See link below for various location options.
• Status: RECRUITING
• Conditions: Advanced Solid Tumors
• Interventions Drug: SPH4336; Drug: Cadonilimab
• Brief Summary: This is a randomized, Open-label, Phase Ib/IIa study to evaluate the efficacy and safety of SPH4336 monotherapy or in combination with Cadonilimab in the patients with selected advanced solid tumors.…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05944224

 

Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors

• Locations: Houston Methodist Hospital, Houston, Texas, 77030, United States
• Status: RECRUITING
• Conditions: Liver Cell Carcinoma; Solid Tumor; Wilms Tumor; Malignant Rhabdoid Tumor; Yolk Sac Tumor; Rhabdomyosarcoma; Liposarcoma; Embryonal Sarcoma of the Liver
• Interventions Genetic: CATCH T cells
• Brief Summary: Patients may be considered if the cancer has come back, has not gone away after standard treatment or the patient cannot receive standard treatment. This research study uses special immune system cells called CATCH T cells, a new experimental treatment…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05103631

 

Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma

• Locations: See link below for various location options.
• Status: RECRUITING
• Conditions: Locally Advanced Extraskeletal Myxoid Chondrosarcoma; Locally Advanced Leiomyosarcoma; Locally Advanced Liposarcoma; Locally Advanced Undifferentiated Pleomorphic Sarcoma; Locally Advanced Unresectable Soft Tissue Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma
• Interventions Procedure: Biopsy; Procedure: Biospecimen Collection; Drug: Cabozantinib; Procedure:Computed Tomography; Biological: Ipilimumab; Procedure: Magnetic Resonance Imaging; Biological:Nivolumab
• Brief Summary: This phase II trial compares the effect of immunotherapy with ipilimumab and nivolumab alone to their combination with cabozantinib in treating patients with soft tissue sarcoma that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced)…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05836571

 

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

• Locations: HonorHealth Research Institute, Scottsdale, Arizona, 85258, United States; NEXT Austin, Austin, Texas, 78758, United States; NEXT Oncology, San Antonio, Texas, 78229, United States
• Status: RECRUITING
• Conditions: Cancer; Tumor, Solid; Malignant Neoplasm; Metastatic Cancer; Advanced Solid Tumor; Non Small Cell Lung Cancer; Melanoma; Head and Neck Squamous Cell Carcinoma; Leiomyosarcoma; Liposarcoma
• Interventions Drug: OR2805; Drug: Cemiplimab; Drug: Docetaxel
• Brief Summary: This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR2805 administered as a monotherapy and in combination with anti-cancer agents in subjects with advanced solid tumors…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05094804

 

Study of the CHK1 Inhibitor BBI-355, an EcDNA-directed Therapy (ecDTx), in Subjects with Tumors with Oncogene Amplifications (POTENTIATE)

• Locations: See link below for various location options.
• Status: RECRUITING
• Conditions: Non-small Cell Lung Cancer; Non-Small Cell Lung Adenocarcinoma; Non-Small Cell Squamous Lung Cancer; Head and Neck Squamous Cell Carcinoma; Esophageal Cancer; Gastric Cancer; Breast Cancer; Bladder Cancer; Ovarian Cancer; Endometrial Cancer; Liposarcoma
• Interventions Drug: BBI-355; Drug: Erlotinib; Drug: Futibatinib
• Brief Summary: BBI-355 is an oral, potent, selective checkpoint kinase 1 (or CHK1) small molecule inhibitor in development as an ecDNA (extrachromosomal DNA) directed therapy (ecDTx). This is a first-in-human, open-label, 3-part, Phase 1/2 study to determine the safety profile and identify the maximum tolerated dose and recommended Phase 2 dose of BBI-355 administered as a single agent or in combination with select therapies…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05827614

 

A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

• Locations: Memorial Sloan Kettering Cancer Center, New York, New York, United States, 10065; University of Texas MD Anderson Cancer Center, Houston, Texas, United States, 77030; Fred Hutchinson Cancer Center, Seattle, Washington, United States, 98109
• Status: RECRUITING
• Conditions: Salivary Gland Tumor; Urothelial Carcinoma; Ovarian Carcinoma; Breast Cancer; Soft Tissue Sarcoma
• Drug: AVA6000
• Brief Summary: This is a first-in-human (FIH), Phase 1 open-label, multicentre dose escalation study investigating AVA6000 monotherapy administered…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04969835

 

A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma

• Locations: Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States, 07920; Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States, 07748; Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States, 07645; Memorial Sloan Kettering Cancer Center Suffolk- Commack, Commack, New York, United States, 11725; Memorial Sloan Kettering Westchester, Harrison, New York, United States, 10604; Memorial Sloan Kettering Cancer Center, New York, New York, United States, 10065; Memorial Sloan Kettering Nassau, Uniondale, New York, United States, 11553
• Status:RECRUITING
• Conditions: Well Differentiated Liposarcoma; Dedifferentiated Liposarcoma: Liposarcoma: Myxoid Liposarcoma; Round Cell Liposarcoma: Myxoid Pleomorphic Liposarcoma; Pleomorphic Liposarcoma; Unresectable Liposarcoma; Unresectablen Dedifferentiated Liposarcoma
• Drugs: Mirdametinib; Palbociclib
• Brief Summary: The purpose of this study is to find out whether mirdametinib in combination with palbociclib is an effective and safe treatment for…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06843967

 

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors 

• Locations: Arnold Palmer Hospital for Children, Orlando, Florida, United States, 32806; St. Joseph’s Children’s Hospital, Tampa, Florida, United States, 33614; Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States, 96813; Children’s Mercy Hospitals and Clinics, Kansas City, Missouri, United States, 64108; Penn State Milton S. Hershey Medical Center and Children’s Hospital, Hershey, Pennsylvania, United States, 17033
• Status: RECRUITING
• Conditions: Neuroblastoma Recurrent; Ewing’s Sarcoma Recurrent; Osteosarcoma Recurrent; Rhabdomyosarcoma Recurrent; Liposarcoma Recurrent
• Drugs: Silmitasertib; Irinotecan; Temozolomide; Vincristine
• Brief Summary: The purpose of this study is to evaluate the investigational drug, silmitasertib (a pill taken by mouth), in combination with FDA approved drugs for solid tumors…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY:NCT06541262

 

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma

• Locations: Memorial Sloan Kettering Westchester, Harrison, New York, United States, 10604; Memorial Sloan Kettering Cancer Center, New York, New York, United States, 10065
• Status: RECRUITING
• Conditions: Uveal Melanoma; Melanoma; Metastatic Uveal Melanoma; Metastatic Melanoma
• Intervention/Treatment: Biological: Lifileucel (LN-144/LN-145)
• Brief Summary: This is an open label study evaluating lifileucel (LN-144) in patients with metastatic uveal melanoma.
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05607095

 

SARC041: Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma

• Locations: University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, Colorado, 80045, United States; Mayo Clinic Florida, Jacksonville, Florida, 32224, United States; Northwestern University, Chicago, Illinois, 60611, United States; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, 02114, United States; Washington University School of Medicine, Saint Louis, Missouri, 63129, United States; Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States; Duke University, Durham, North Carolina, 27710, United States; Oregon Health & Science University, Portland, Oregon, 97239, United States; University of Washington, Seattle, Washington, 98109, United States
• Status: ACTIVE, NOT RECRUITING
• Conditions: Advanced Dedifferentiated Liposarcoma
• Interventions Drug: Abemaciclib; Drug: Placebo
• Brief Summary: This is a Phase 3 randomized double-blind study of abemaciclib versus placebo. Patients with progression of disease will cross over to open label abemaciclib… For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04967521

 

A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma

• Locations: Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, 07920, United States; Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, 07748, United States; Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, 07645, United States; Memorial Sloan Kettering Suffolk – Commack (Limited Protocol Activities), Commack, New York, 11725, United States; Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, 10604, United States; Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States; Memorial Sloan Kettering Nassau (Limited protocol activities), Rockville Centre, New York, 11553, United States
• Status: ACTIVE, NOT RECRUITING
• Conditions: Dedifferentiated Liposarcoma; Soft Tissue Sarcoma; Sarcoma,Soft Tissue; Sarcoma; Recurrent Dedifferentiated Liposarcoma; Unresectable Dedifferentiated Liposarcoma; Metastatic Dedifferentiated Liposarcoma
• Interventions Drug: Etrumadenant; Drug: Zimberelimab
• Brief Summary: Participants will have a diagnosis of dedifferentiated liposarcoma (DDLS) that has spread beyond its original location (advanced)…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05886634

 

Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

• Locations: See link below for various location options.
• Status: ACTIVE, NOT RECRUITING
• Conditions: Synovial Sarcoma; Myxoid Liposarcoma
• Interventions Genetic: afamitresgene autoleucel (previously ADP-A2M4)
• Brief Summary: This is a study to investigate the efficacy and safety of ADP-A2M4 in HLA-A*02 eligible and MAGE-A4 positive subjects with metastatic or inoperable (advanced) Synovial Sarcoma (Cohort 1, 2 and 3 ) or MRCLS (Cohort 1) …
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04044768

 

Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma (DOSa)

• Locations: M D Anderson Cancer Center, Houston, Texas, 77030, United States
• Status: ACTIVE, NOT RECRUITING
• Conditions: Metastatic Angiosarcoma; Metastatic Dedifferentiated Liposarcoma; Metastatic Osteosarcoma; Recurrent Angiosarcoma; Recurrent Dedifferentiated Liposarcoma; Recurrent Osteosarcoma; Refractory Dedifferentiated Liposarcoma; Refractory Osteosarcoma
• Interventions Biological: Durvalumab; Biological: Oleclumab
• Brief Summary: This phase II trial investigates how well oleclumab and durvalumab work in treating patients with sarcoma that has come back (recurrent) or does not respond to treatment (refractory) or has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as oleclumab and durvalumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread…
  For up-to-date information including open recruiting locations and eligibility, click here:STUDY: NCT04668300

 

Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma

• Locations: See link below for various location options.
• Status: ACTIVE, NOT RECRUITING
• Conditions: Advanced Dedifferentiated Liposarcoma; Locally Advanced Dedifferentiated Liposarcoma; Metastatic Dedifferentiated Liposarcoma; Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8; Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8; Unresectable Dedifferentiated Liposarcoma
• Interventions Drug: Palbociclib; Biological: Cemiplimab; Procedure: Magnetic Resonance Imaging; Procedure:Computed Tomography; Procedure: Biospecimen collection; Other: Questionnaire Administration
• Brief Summary: This phase II trial compares the effect of treatment with palbociclib alone to treatment with palbociclib plus cemiplimab for treating patients with dedifferentiated liposarcoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) …
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05694871

 

NM32-2668 in Adult Patients With Selected Advanced Solid Tumors

• Locations: USC Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States; Duke University, Durham, North Carolina, 27710, United States; Cleveland Clinic, Cleveland, Ohio, 44195, United States; University of Pittsburgh Medical Center (UPMC) – Hillman Cancer Center, Pittsburgh, Pennsylvania, 15232, United States; Lifespan Cancer Institute at Rhode Island Hospital, Providence, Rhode Island, 02903, United States; Mary Crowley Cancer Research, Dallas, Texas, 75230, United States
• Status: ACTIVE, NOT RECRUITING
• Conditions: Ovarian Carcinoma; Fallopian Tube Carcinoma; Peritoneal Carcinoma; Endometrial Cancer; Adenocarcinoma of Lung; Triple Negative Breast Cancer; Liposarcoma; Leiomyosarcoma; Mesothelioma, Malignant; Adenocarcinoma – Gastroesophageal Junction (GEJ); Adenocarcinoma of the Stomach; Melanoma, Malignant; Renal Cell Carcinoma
• Interventions Biological: NM32-2668
• Brief Summary: This is a first-in-human, open-label, multi-center, Phase 1, dose-escalation study with expansion cohorts to evaluate NM32-2668 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose, define the pharmacokinetics, to explore the pharmacodynamics, and to obtain preliminary evidence of the clinical activity in adult patients with selected advanced solid tumors…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06299163

 

Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma

• Locations: University of Alabama at Birmingham, Birmingham, Alabama, United States, 35249; Mayo Clinic-Arizona, Phoenix, Arizona, United States, 85054; Precision NextGen Oncology, Beverly Hills, California, United States, 90212; Sarcoma Oncology Center, Santa Monica, California, United States, 90403; University of California Los Angeles, Santa Monica, California, United States, 90404; Yale Cancer Center, New Haven, Connecticut, United States, 06510; Mayo Clinic – Florida, Jacksonville, Florida, United States, 32224; University Cancer and Blood Center, Athens, Georgia, United States, 30607; Northwestern University, Chicago, Illinois, United States, 60611; University of Kansas Cancer Center, Overland Park, Kansas, United States, 66210; Mayo Clinic, Rochester, Rochester, Minnesota, United States, 55905; Washington University School of Medicine, Saint Louis, Missouri, United States, 63108; Nebraska Methodist Hospital, Omaha, Nebraska, United States, 68114; John Theurer Cancer Center, Hackensack, New Jersey, United States, 07601; Northwell Health, Lake Success, New York, United States, 11042; Memorial Sloan-Kettering Cancer Center, New York, New York, United States, 10065; Duke University Medical Center, Durham, North Carolina, United States, 27710; Abramson Cancer Center at Pennsylvania Hospital, Philadelphia, Pennsylvania, United States, 19106; West Cancer Center & Research Institute, Germantown, Tennessee, United States, 38138; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States, 77030; Utah Cancer Specialists Cancer Center, Salt Lake City, Utah, United States, 84106; Huntsman Cancer Institute, Salt Lake City, Utah, United States, 84112; Virginia Cancer Specialists, PC, Fairfax, Virginia, United States, 22031; Fred Hutchinson Cancer Research Center, Seattle, Washington, United States, 98109; Medical Oncology Associates, P.S, Spokane, Washington, United States, 99208; Froedtert and The Medical College of Wisconsin, Milwaukee, Wisconsin, United States, 53226
• Status: ACTIVE, NOT RECRUITING
• Conditions: Liposarcoma, Dedifferentiated
• Drug: Brigimadlin
• Brief Summary: This study is open to adults with a type of cancer called dedifferentiated liposarcoma (DDLPS). They can join the study if their tumours are positive for MDM2. The purpose of this study is to find out…
  For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06058793

 

Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

• Locations: University of Alabama at Birmingham, Birmingham, Alabama, United States, 35233; University of Arizona, Tucson, Arizona, United States, 85719; Precision NextGen Oncology, Beverly Hills, California, United States, 90212; City of Hope-Duarte-56419, Duarte, California, United States, 91010; University of Southern California, Los Angeles, California, United States, 90033; Sarcoma Oncology Center, Santa Monica, California, United States, 90403; Mayo Clinic Cancer Center, Jacksonville, Florida, United States, 32224; Winship Cancer Institute, Atlanta, Georgia, United States, 30322; Massachusetts General Hospital, Boston, Massachusetts, United States, 02114; Dana-Farber Cancer Institute, Boston, Massachusetts, United States, 02215; University of Michigan Health System, Ann Arbor, Michigan, United States, 48109; Mayo Clinic, Rochester, Rochester, Minnesota, United States, 55905; Barnes-Jewish Hospital, Saint Louis, Missouri, United States, 63110; Nebraska Cancer Specialists-Omaha-69502, Omaha, Nebraska, United States, 68114; University Hospitals of Cleveland, Cleveland, Ohio, United States, 44106; Oregon Health and Sciences University, Portland, Oregon, United States, 97239; Henry-Joyce Cancer Clinic, Nashville, Tennessee, United States, 37232; University of Texas Southwestern Medical Center, Dallas, Texas, United States, 75390; Huntsman Cancer Institute, Salt Lake City, Utah, United States, 84112; Froedtert and The Medical College of Wisconsin, Milwaukee, Wisconsin, United States, 53226
• Status: ACTIVE, NOT RECRUITING
• Conditions: Liposarcoma, Dedifferentiated
• Drugs: Brigimadlin (BI 907828), Doxorubicin
• Brief Summary: This study is open to people with a type of cancer called dedifferentiated liposarcoma. People with advanced liposarcoma aged 18 or older who are not receiving any other cancer treatment can participate…

For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05218499